Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti–Hepatocyte Growth Factor Antibody Ficlatuzumab-Reference-Cited by-同舟云学术

Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti–Hepatocyte Growth Factor Antibody Ficlatuzumab

Published:2015-12-01 Issue:12 Volume:141 Page:1133
ISSN:2168-6181
Container-title:JAMA Otolaryngology–Head & Neck Surgery
language:en
Short-container-title:JAMA Otolaryngol Head Neck Surg

Author:

Kumar Dhruv¹,Kandl Christopher¹,Hamilton Chase D’Arcy¹,Shnayder Yelizaveta¹,Tsue Terance Ted¹,Kakarala Kiran¹,Ledgerwood Levi¹,Sun Xiuzhi Susan²,Huang Hongzhou (John)³,Girod Douglas¹,Thomas Sufi Mary⁴

Affiliation:

1. Department of Otolaryngology, University of Kansas Medical Center, Kansas City

2. Departments of Grain Science and Industry, and Biological and Agricultural Engineering, Kansas State University, Kansas City

3. PepGel LLC, Manhattan, Kansas

4. Department of Otolaryngology, University of Kansas Medical Center, Kansas City4Department of Cancer Biology, University of Kansas Medical Center, Kansas City5Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City6Universi

Publisher

American Medical Association (AMA)

Subject

Otorhinolaryngology,Surgery

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Head and neck cancer: pathogenesis and targeted therapy;MedComm;2024-08-21

2. Crosstalk between CAFs and tumour cells in head and neck cancer;Cell Death Discovery;2024-06-26

3. Advanced Hydrogel for Physiological 3D Colonies of Pluripotent Stem Cells;Advances in Pluripotent Stem Cells;2024-01-31

4. Unlocking the Potential of Human-Induced Pluripotent Stem Cells: Cellular Responses and Secretome Profiles in Peptide Hydrogel 3D Culture;Cells;2024-01-12

5. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer;Journal of Clinical Oncology;2023-08-01